التفاصيل البيبلوغرافية
| العنوان: |
Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis. |
| المؤلفون: |
Mercuri, Eugenio1,2 (AUTHOR) eugeniomaria.mercuri@unicatt.it, Osorio, Andrés Nascimento3 (AUTHOR), Muntoni, Francesco4,5 (AUTHOR), Buccella, Filippo6 (AUTHOR), Desguerre, Isabelle7 (AUTHOR), Kirschner, Janbernd8 (AUTHOR), Tulinius, Már9 (AUTHOR), de Resende, Maria Bernadete Dutra10 (AUTHOR), Morgenroth, Lauren P.11 (AUTHOR), Gordish-Dressman, Heather12 (AUTHOR), Johnson, Shelley13 (AUTHOR), Kristensen, Allan13 (AUTHOR), Werner, Christian14 (AUTHOR), Trifillis, Panayiota13 (AUTHOR), Henricson, Erik K.15 (AUTHOR), McDonald, Craig M.15 (AUTHOR) |
| المصدر: |
Journal of Neurology. Aug2023, Vol. 270 Issue 8, p3896-3913. 18p. |
| مصطلحات موضوعية: |
*NONSENSE mutation, *NATURAL history, *DUCHENNE muscular dystrophy, *PROPENSITY score matching, *VITAL capacity (Respiration) |
| مستخلص: |
Objective: Strategic Targeting of Registries and International Database of Excellence (STRIDE) is an ongoing, international, multicenter registry of real-world ataluren use in individuals with nonsense mutation Duchenne muscular dystrophy (nmDMD) in clinical practice. This updated interim report (data cut-off: January 31, 2022), describes STRIDE patient characteristics and ataluren safety data, as well as the effectiveness of ataluren plus standard of care (SoC) in STRIDE versus SoC alone in the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS). Methods: Patients are followed up from enrollment for at least 5 years or until study withdrawal. Propensity score matching was performed to identify STRIDE and CINRG DNHS patients who were comparable in established predictors of disease progression. Results: As of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 4.5 (3.7) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (56.8) days. Ataluren had a favorable safety profile; most treatment-emergent adverse events were mild or moderate and unrelated to ataluren. Kaplan–Meier analyses demonstrated that ataluren plus SoC significantly delayed age at loss of ambulation by 4 years (p < 0.0001) and age at decline to %-predicted forced vital capacity of < 60% and < 50% by 1.8 years (p = 0.0021) and 2.3 years (p = 0.0207), respectively, compared with SoC alone. Conclusion: Long-term, real-world treatment with ataluren plus SoC delays several disease progression milestones in individuals with nmDMD. NCT02369731; registration date: February 24, 2015. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
